Conatus Pharmaceuticals to conduct initial public offering of stock

Proceeds used for clinical development of emricasan, working capital

By Devika Patel

Knoxville, Tenn., June 14 - Conatus Pharmaceuticals Inc. will price an initial public sale of its common stock, according to a Form S-1 filed Friday with the Securities and Exchange Commission. The company expects its shares will trade on the Nasdaq under the symbol "CNAT."

The deal will have a 30-day greenshoe.

Stifel, Nicolaus & Co. Inc., Piper Jaffray & Co., JMP Securities and SunTrust Robinson Humphrey Inc. are assisting.

Proceeds will be used for the clinical development of emricasan, working capital and general corporate purposes.

The biotechnology company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.